These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives. Belema M; Nguyen VN; St Laurent DR; Lopez OD; Qiu Y; Good AC; Nower PT; Valera L; O'Boyle DR; Sun JH; Liu M; Fridell RA; Lemm JA; Gao M; Knipe JO; Meanwell NA; Snyder LB Bioorg Med Chem Lett; 2013 Aug; 23(15):4428-35. PubMed ID: 23803586 [TBL] [Abstract][Full Text] [Related]
10. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742. Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742 [TBL] [Abstract][Full Text] [Related]
11. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors. Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481 [TBL] [Abstract][Full Text] [Related]
12. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity. Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core. Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390 [TBL] [Abstract][Full Text] [Related]
14. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 1. Tran TD; Wakenhut F; Pickford C; Shaw S; Westby M; Smith-Burchnell C; Watson L; Paradowski M; Milbank J; Brimage RA; Halstead R; Glen R; Wilson CP; Adam F; Hay D; Chiva JY; Nichols C; Blakemore DC; Gardner I; Dayal S; Pike A; Webster R; Pryde DC ChemMedChem; 2014 Jul; 9(7):1378-86. PubMed ID: 24729513 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors. Ivashchenko AA; Ivanenkov YA; Aladinskiy VA; Karapetian RN; Koryakova AG; Ryakhovskiy AA; Mitkin OD; Kravchenko DV; Savchuk NP; Zagribelnyy BA; Ivashchenko AV Bioorg Med Chem; 2020 Oct; 28(20):115716. PubMed ID: 33069072 [TBL] [Abstract][Full Text] [Related]
16. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559 [TBL] [Abstract][Full Text] [Related]